The Cure Parkinson’s Trust is honoured that our Director of Research, Dr Richard Wyse (above), is co-editor of a new Cochrane Report titled ‘GLP‐1 receptor agonists for Parkinson's disease’ - read the report here. The article explores the potential neuroprotective effects of GLP-1 receptor agonists (currently used to treat type 2 diabetes by stimulating the release of insulin) in conditions such as Parkinson’s.

The Cochrane Library is a revered collection database that contains high-quality, independent evidence to inform healthcare decision-making.

Dr Richard Wyse said:

It is a huge honour to be invited to contribute to a Cochrane Report which has, for the past 20 years been globally recognized as representing the highest standard in evidence-based health care. This report, draws attention to the future potential treatment of Parkinson's disease by GLP-1 agonist drugs, which is a growing and important area of clinical research, and which has been spearheaded in recent years by The Cure Parkinson’s Trust who have launched trials of Exenatide, Liraglutide and Lixisenatide in various groups of Parkinsons patients, with some trials already completed.  Since the report was commissioned, we have seen further growth in this important area of research with the start of the Neuraly trials (NY001) and the Korean company, Peptron, also starting clinical trials.

Read more on CPT’s work with GLP-1 receptor agonists.